Phase II study of combination of the HyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB)

被引：6
|
作者：
Ravandi, Farhad [1 ]
Thomas, Deborah [1 ]
Kantarjian, Hagop [1 ]
Faderl, Stefan [1 ]
Koller, Charles [1 ]
Brown, Devri [1 ]
Garris, Rebecca [1 ]
Borthakur, Gautam [1 ]
Burger, Jan [1 ]
Kebriaei, Partow [1 ]
Jorgensen, Jeffrey [1 ]
Jones, Dan [1 ]
Cortes, Jorge [1 ]
O'Brien, Susan [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2814.2814
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2814
引用
收藏
页码：828A / 828A
页数：1
相关论文
共 50 条
  • [1] Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB)
    Liu-Dumlao, Theresa
    O'Brien, Susan
    Cortes, Jorge E.
    Thomas, Deborah A.
    Faderl, Stefan
    Jabbour, Elias
    Koller, Charles
    Garris, Rebecca
    Kebriaei, Partow
    Champlin, Richard
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Kantarjian, Hagop M.
    Ravandi, Farhad
    BLOOD, 2011, 118 (21) : 1106 - 1106
  • [2] Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge
    Thomas, Deborah A.
    Faderl, Stefan
    Jones, Dan
    Jabbour, Elias
    Koller, Charles
    Dara, Samuel
    Garris, Rebecca
    Kebriaei, Partow
    Borthakur, Gautam
    Ferrajoli, Alessandra
    O'Brien, Susan
    BLOOD, 2009, 114 (22) : 806 - 807
  • [3] Combination of the hyperCVAD Regimen with Dasatinib is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)
    Jabbour, Elias
    O'Brien, Susan
    Thomas, Deborah A.
    Faderl, Stefan
    Koller, Charles Asa
    Dara, Samuel
    Garris, Rebecca
    Cortes, Jorge
    Kantadian, Hagop M.
    Ravandi, Farhad
    BLOOD, 2008, 112 (11) : 1004 - 1004
  • [4] Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
    Benjamini, Ohad
    Dumlao, Theresa Liu
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Jorgensen, Jeffrey
    Luthra, Rajyalakshmi
    Garris, Rebecca
    Thomas, Deborah
    Kebriaei, Partow
    Champlin, Richard
    Jabbour, Elias
    Burger, Jan
    Cortes, Jorge
    Ravandi, Farhad
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (03) : 282 - 287
  • [5] Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Faderl, Stefan
    Jones, Dan
    Koller, Charles A.
    Dara, Samuel
    Garris, Rebecca
    Kebriaei, Partow
    Champlin, Richard
    Borthakur, Gautam
    Wierda, William G.
    Burger, Jan A.
    Cortes, Jorge
    O'Brien, Susan
    BLOOD, 2009, 114 (22) : 345 - 345
  • [6] Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
    Ravandi, Farhad
    Thomas, Deborah
    Kantarjian, Hagop
    Faderl, Stefan
    Koller, Charles
    Dara, Samuel
    Garris, Rebecca
    Kebriaei, Partow
    Borthakur, Gautam
    Wierda, William
    Burger, Jan
    Cortes, Jorge
    O'Brien, Susan
    BLOOD, 2008, 112 (11) : 1005 - 1005
  • [7] Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph plus ) acute lymphoblastic leukemia (ALL)
    Ravandi, F.
    Faderl, S.
    Thomas, D. A.
    Brown, D.
    Garris, R.
    Borthakur, G.
    Ferrajoli, A.
    Cortes, J. E.
    Kantarjian, H. M.
    O'Brien, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] LINEAGE INVOLVEMENT OF BCR-ABL IN PHILADELPHIA-CHROMOSOME-POSITIVE (PH+) LYMPHOBLASTIC MALIGNANCIES - CHRONIC MYELOGENOUS LEUKEMIA (CML) PRESENTING IN LYMPHOID BLAST PHASE (CML-LBP) VS PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    ANASTASI, J
    FENG, J
    LEBEAU, MM
    RUBIN, CM
    LARSON, RA
    ROWLEY, JD
    VARDIMAN, JW
    LABORATORY INVESTIGATION, 1995, 72 (01) : A105 - A105
  • [9] Dasatinib population pharmacokinetics in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ph plus all)
    Dai, Guowei
    Roy, Amit
    Mandava, Mohan
    Blackwood-Chirchir, Anne
    Luo, Roger
    Wu, Chiyuan
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
  • [10] Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL).
    O'Brien, Susan Mary
    Jabbour, Elias
    Thomas, Deborah A.
    Ravandi, Farhad
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Garris, Rebecca
    Jeanis, Vicky
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345